@parisiadoulab.bsky.social
Reposted
Leucine-rich repeat kinase 2 impairs the release sites of Parkinson's disease vulnerable dopamine axons #NeuroDegeneration 🧪🧠
https://www.researchsquare.com/article/rs-7518988/latest
https://www.researchsquare.com/article/rs-7518988/latest
September 12, 2025 at 7:02 AM
Leucine-rich repeat kinase 2 impairs the release sites of Parkinson's disease vulnerable dopamine axons #NeuroDegeneration 🧪🧠
https://www.researchsquare.com/article/rs-7518988/latest
https://www.researchsquare.com/article/rs-7518988/latest
🚨Preprint alert! 🚨 Deregulation of the most vulnerable dopamine neuron subtypes by LRRK2; a collaborative effort of various labs—just the way science should advance. Thanks to my colleagues, trainees, and ASAP for their support.@asapresearch.parkinsonsroadmap.org #Parkinson's
lnkd.in/eh2xv9hp
lnkd.in/eh2xv9hp
LinkedIn
This link will take you to a page that’s not on LinkedIn
lnkd.in
August 29, 2025 at 10:46 AM
🚨Preprint alert! 🚨 Deregulation of the most vulnerable dopamine neuron subtypes by LRRK2; a collaborative effort of various labs—just the way science should advance. Thanks to my colleagues, trainees, and ASAP for their support.@asapresearch.parkinsonsroadmap.org #Parkinson's
lnkd.in/eh2xv9hp
lnkd.in/eh2xv9hp
The best way to start the weekend!
Perseverance is not giving up. It is persistence and tenacity, the effort required to do something and keep doing it till the end, even if it's hard
Perseverance is not giving up. It is persistence and tenacity, the effort required to do something and keep doing it till the end, even if it's hard
June 29, 2025 at 2:33 AM
The best way to start the weekend!
Perseverance is not giving up. It is persistence and tenacity, the effort required to do something and keep doing it till the end, even if it's hard
Perseverance is not giving up. It is persistence and tenacity, the effort required to do something and keep doing it till the end, even if it's hard
🥳🍾Our latest research has just been published in Molecular Psychiatry @springernature.com.
We showed that inhibiting Parkinson's disease kinase LRRK2 ameliorates the antipsychotic's motor side effects that mimic Parkinsonian phenotypes @asapresearch.parkinsonsroadmap.org rdcu.be/ei2K5
We showed that inhibiting Parkinson's disease kinase LRRK2 ameliorates the antipsychotic's motor side effects that mimic Parkinsonian phenotypes @asapresearch.parkinsonsroadmap.org rdcu.be/ei2K5
LRRK2 mediates haloperidol-induced changes in indirect pathway striatal projection neurons
Molecular Psychiatry - LRRK2 mediates haloperidol-induced changes in indirect pathway striatal projection neurons
rdcu.be
April 26, 2025 at 8:38 PM
🥳🍾Our latest research has just been published in Molecular Psychiatry @springernature.com.
We showed that inhibiting Parkinson's disease kinase LRRK2 ameliorates the antipsychotic's motor side effects that mimic Parkinsonian phenotypes @asapresearch.parkinsonsroadmap.org rdcu.be/ei2K5
We showed that inhibiting Parkinson's disease kinase LRRK2 ameliorates the antipsychotic's motor side effects that mimic Parkinsonian phenotypes @asapresearch.parkinsonsroadmap.org rdcu.be/ei2K5